BioCentury
ARTICLE | Company News

Chiromics in pair of pharma discovery deals

November 10, 2012 1:54 AM UTC

Chiromics LLC (Princeton, N.J.) announced separate deals on Friday with Bristol-Myers Squibb Co. (NYSE:BMY) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to discover small molecules against undisclosed targets. Bristol-Myers will receive a non-exclusive license to Chiromics' chemical compound library and an exclusive license to a proprietary compound collection. Using its Chalis hit recognition algorithm, Chiromics will also discover and optimize compounds in its libraries against targets provided by Bristol-Myers. Bristol-Myers declined to disclose details of its deal with Chiromics, while GSK could not be reached. Chiromics also could not be reached for details. ...